Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × capmatinib × Clear all

Phase

Phase 2/3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Neoplasms 1 Liver Neoplasms 1 Gliosarcoma 1 Glioblastoma 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

pembrolizumab 39 Gemcitabine 26 Nivolumab 24 Paclitaxel 17 Cisplatin 14 Carboplatin 14 Cyclophosphamide 12 Capecitabine 11 Ipilimumab 10 Irinotecan 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 Docetaxel 8 Dexamethasone 8 Bevacizumab 8 Rituximab 7 spartalizumab 6 cemiplimab 6 Temozolomide 6 Sorafenib 6 Pemetrexed 6 Cetuximab 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5 ibrutinib 5 fludarabine 5 Radiotherapy 5 Prednisone 5 avelumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡